Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Ascletis Pharma, Inc. ( (HK:1672) ) is now available.
Ascletis Pharma Inc. announced a voluntary lock-up undertaking by its controlling shareholders, Dr. Jinzi Jason Wu and Mrs. Judy Hejingdao Wu, who have committed not to dispose of their shares until the completion of key clinical studies. This move reflects their confidence in the company’s long-term prospects and aims to reassure investors about the company’s future developments in obesity treatment. The lock-up involves 575,952,078 shares, representing approximately 58.03% of the company’s total shares, and is linked to the outcomes of clinical trials expected by the end of 2025.
The most recent analyst rating on (HK:1672) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative therapies for liver diseases, viral infections, and cancer. The company is incorporated in the Cayman Islands and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 8,345,900
Technical Sentiment Signal: Buy
Current Market Cap: HK$14.17B
For an in-depth examination of 1672 stock, go to TipRanks’ Overview page.